NOD2 maybe a biomarker for the survival of kidney cancer patients

作者：Deguo Xu, Shuisheng Zhang, Shenfeng Zhang, Hongmei Liu, Paiyun Li, Lili Yu, Heli Shang, Yong Hou, Yuan Tian · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.21547 · 被引用次数：26 · 研究领域：Ferroptosis and cancer prognosis、Clusterin in disease pathology、Bioinformatics and Genomic Networks

// Deguo Xu 1, * , Shuisheng Zhang 2, * , Shenfeng Zhang 3, * , Hongmei Liu 1, * , Paiyun Li 4, * , Lili Yu 1 , Heli Shang 1 , Yong Hou 1 and Yuan Tian 1 1 Department of Radiation Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong Province 250014, P.R. China 2 Department of Abdominal Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China 3 Department of Oncology, Zaozhuang Municipal Hospital of Shandong Province, Shizhong District, Zaozhuang, Shandong Province 277101, P.R. China 4 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Aetiology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China * These authors contributed equally to this work Correspondence to: Yuan Tian, email: tytytianyuan@aliyun.com Keywords: NOD2 gene, kidney cancer, survival, prognosis Received: August 02, 2017      Accepted: September 20, 2017      Published: October 06, 2017 ABSTRACT Background: Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) may play an important role in the outcome of kidney cancer patients. To explore the relationship between NOD2 and the prognosis of kidney cancer patients, a databank-based reanalysis was conducted. Materials and Methods: Data related to kidney cancer patients at least with survival...